Omeros (OMER) Non-Current Assets (2010 - 2026)
Omeros (OMER) posted Non-Current Assets of $105.8 million for Q1 2026, down 3.77% sequentially from $110.0 million in Q4 2025, and down 23.86% YoY from $139.0 million in Q1 2025.
Omeros (OMER) Non-Current Assets (2010 - 2026) Analysis & Trends
Omeros has reported Non-Current Assets for 17 years, with the latest figure at $105.8 million in Q1 2026.
- Quarterly Non-Current Assets fell 23.86% year-over-year to $105.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $460.6 million (down 21.09% YoY) and the FY2025 annual result came in at $110.0 million, down 23.08% from the prior year.
- Non-Current Assets slipped to $105.8 million in Q1 2026 per OMER's latest filing, from $110.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $169.0 million in Q3 2022 and troughed at $105.8 million in Q1 2026.
- A 5-year average of $142.0 million and a median of $143.1 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 449.14% in 2022, then slipped 23.86% in 2026.
- Over 5 years, Non-Current Assets stood at $147.7 million in 2022, then grew by 8.55% to $160.4 million in 2023, then dropped by 10.86% to $143.0 million in 2024, then dropped by 23.08% to $110.0 million in 2025, then retreated by 3.77% to $105.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $105.8 million, $110.0 million, and $113.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 101.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101.59 Mn |
| Mar 31, 2026 | 105.82 Mn |
| Dec 31, 2025 | 109.97 Mn |
| Sep 30, 2025 | 113.90 Mn |
| Jun 30, 2025 | 130.92 Mn |
| Mar 31, 2025 | 138.98 Mn |
| Dec 31, 2024 | 142.96 Mn |
| Sep 30, 2024 | 148.41 Mn |
| Jun 30, 2024 | 153.38 Mn |
| Mar 31, 2024 | 156.53 Mn |
| Dec 31, 2023 | 160.37 Mn |
| Sep 30, 2023 | 141.73 Mn |
| Jun 30, 2023 | 138.86 Mn |
| Mar 31, 2023 | 143.10 Mn |
| Dec 31, 2022 | 147.73 Mn |
| Sep 30, 2022 | 169.01 Mn |
| Jun 30, 2022 | 152.92 Mn |
| Mar 31, 2022 | 159.04 Mn |
| Dec 31, 2021 | 171.31 Mn |
| Sep 30, 2021 | 32.08 Mn |